COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
USU Acquires SaaS Management Software Provider saasmetrix and Strengthens Innovation Leadership
USU acquires SaaS management software provider saasmetrix, strengthening innovation leadership. Enhanced SaaS platform offers automation, cost reduction, and security management. Expands target groups and market opportunities -
-
COMMUNIQUÉ DE PRESSE
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Publication des informations sur le nombre total d'actions et de droits de vote de Vivendi au 28 février 2025 conformément à l'article 223-16 du Règlement Général de l’AMF -
COMMUNIQUÉ DE PRESSE
u-blox introduces PointPerfect Live, bringing fast, reliable, and scalable network RTK to high-precision GNSS applications
u-blox launches PointPerfect Live, a network RTK correction service for high-precision GNSS applications. Real-time centimeter-level accuracy for surveying, construction, mining, agriculture -
COMMUNIQUÉ DE PRESSE
Original-Research: Scandinavian Astor Group AB (von NuWays AG): Buy
Scandinavian Astor Group AB shows strong financial performance in Q4 results with significant sales growth, EBITDA improvement, and cash generation. Anticipation of further M&A deals in 2025. Raised target price to SEK 30.00 -
-
COMMUNIQUÉ DE PRESSE
Preliminary figures for Medios AG 2024: Significant increase in earnings and margins – positive outlook for 2025
Medios AG reports significant increase in earnings and margins for 2024, positive outlook for 2025. Preliminary figures show revenue reaching €1.9 billion and EBITDA pre1 around €79 million -
-
COMMUNIQUÉ DE PRESSE
AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch
AB Science's masitinib and its phase 3 principal investigator, neurologist Patrick Vermersch, featured in Life Sciences Magazine for potential breakthrough in Progressive MS Treatment
